Finally, a phase 2 clinical trial to assess the activity of a strong selective inhibitor for AURKA, ENMD- 2076, in treating patients with ovarian clear cell carcinomas was recently concluded (NCT01914510). Here, AURKA is linked to ovarian clear cell cancer.